Genus-Wide Chlamydial Peptide Vaccine Antigens
AssigneeWayne State University
InventorsJudith Whittum-Hudson, Alan P. Hudson
Life of this patent
Estimating the term…
Loading patent…
AssigneeWayne State University
InventorsJudith Whittum-Hudson, Alan P. Hudson
Estimating the term…
Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to antigen-binding regions of an anti-idiotypic antibody (mAb2) specific for anti-GLXA antibody (Ab1) which act as molecular mimics of GLXA are also disclosed used as immunogens to induce broadly reactive genus-specific anti-chlamydial antibodies. These peptides and immunogenic DNA encoding the mAb2-like peptides, microparticle or nanoparticle formulations and other formulations of these peptides are disclosed as are methods for immunizing subjects to obtain genus-specific anti-chlamydial antibodies and to treat or prevent Chlamydia-associated or induced rheumatoid arthritis.
An immunogenic peptide of at least about 10 amino acids in length, but shorter than the length of an antibody VH or VL domain or an scFV chain, which peptide mimics immunologically the structure of chlamydia genus-specific glycolipid exoantigen (GLXA) so that when the peptide is administered to a mammalian subject in an adequate amount and immunogenic form, it induces an antibody response that is measurable in:
(canceled)
26-29. (canceled)
An immunogenic DNA molecule encoding a polypeptide that comprises, in any order, one, two or three complementarity-determining regions (CDRs) of a heavy chain or light chain variable region of an Ab2 anti-idiotypic antibody specific for an Ab1 anti-GLXA antibody.
(canceled)
Dependencies are inferred from the claim text.